|
[1]
|
Eslam, M., Newsome, P.N., Sarin, S.K., Anstee, Q.M., Targher, G., Romero-Gomez, M., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Eslam, M., Sarin, S.K., Wong, V.W., Fan, J., Kawaguchi, T., Ahn, S.H., et al. (2020) The Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the Diagnosis and Management of Metabolic Associated Fatty Liver Disease. Hepatology International, 14, 889-919. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Portincasa, P. (2023) NAFLD, MAFLD, and Beyond: One or Several Acronyms for Better Comprehension and Patient Care. Internal and Emergency Medicine, 18, 993-1006. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., et al. (2024) Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options. International Journal of Molecular Sciences, 25, Article No. 5640. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Song, S.J., Lai, J.C., Wong, G.L., Wong, V.W. and Yip, T.C. (2024) Can We Use Old NAFLD Data under the New MASLD Definition? Journal of Hepatology, 80, e54-e56. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Zhou, X., Targher, G., Byrne, C.D., Somers, V., Kim, S.U., Chahal, C.A.A., et al. (2023) An International Multidisciplinary Consensus Statement on MAFLD and the Risk of CVD. Hepatology International, 17, 773-791. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Wang, T., Wang, R., Bu, Z., Targher, G., Byrne, C.D., Sun, D., et al. (2022) Association of Metabolic Dysfunction-Associated Fatty Liver Disease with Kidney Disease. Nature Reviews Nephrology, 18, 259-268. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Tilg, H., Byrne, C.D., et al. (2021) Non-Alcoholic Fatty Liver Disease and Increased Risk of Incident Extrahepatic Cancers: A Meta-Analysis of Observational Cohort Studies. Gut, 71, 778-788. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Gao, F., Chen, G., Byrne, C.D., Targher, G., Cheung, T.T. and Zheng, M. (2023) Metabolic Dysfunction-Associated Fatty Liver Disease and Hepatocellular Carcinoma: Present and Future. Hepatobiliary Surgery and Nutrition, 12, 945-948. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Lou, T., Yang, R. and Fan, J. (2024) The Global Burden of Fatty Liver Disease: The Major Impact of China. Hepatobiliary Surgery and Nutrition, 13, 119-123. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Lonardo, A., Mantovani, A., Petta, S., Carraro, A., Byrne, C.D. and Targher, G. (2022) Metabolic Mechanisms for and Treatment of NAFLD or NASH Occurring after Liver Transplantation. Nature Reviews Endocrinology, 18, 638-650. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Kaylan, K.B. and Paul, S. (2024) NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Current Diabetes Reports, 25, Article No. 5. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Kwo, P.Y., Cohen, S.M. and Lim, J.K. (2017) ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. American Journal of Gastroenterology, 112, 18-35. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., et al. (2015) High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. The Journal of Clinical Endocrinology & Metabolism, 100, 2231-2238. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Loomba, R. and Adams, L.A. (2019) The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by Nash. Hepatology, 70, 1885-1888. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Mantovani, A., Byrne, C.D., Bonora, E. and Targher, G. (2018) Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-Analysis. Diabetes Care, 41, 372-382. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Patel, S., Siddiqui, M.B., Roman, J.H., Zhang, E., Lee, E., Shen, S., et al. (2021) Association between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 19, 2202-2204. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Vali, Y., Lee, J., Boursier, J., Petta, S., Wonders, K., Tiniakos, D., et al. (2023) Biomarkers for Staging Fibrosis and Non-Alcoholic Steatohepatitis in Non-Alcoholic Fatty Liver Disease (the LITMUS Project): A Comparative Diagnostic Accuracy Study. The Lancet Gastroenterology & Hepatology, 8, 714-725. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., et al. (2015) Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD after up to 33 Years of Follow-Up. Hepatology, 61, 1547-1554. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Li, Y., Dai, C., Ruan, Y., Yang, H., Zeng, H., Huang, R., et al. (2024) Metabolic Dysfunction-Associated Fatty Liver Disease and Nonalcoholic Fatty Liver Disease from Clinical to Pathological Characteristics: A Multi-Center Cross-Sectional Study in Real World. Postgraduate Medical Journal, 100, 319-326. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Rinella, M.E., Neuschwander-Tetri, B.A., Siddiqui, M.S., Abdelmalek, M.F., Caldwell, S., Barb, D., et al. (2023) AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology, 77, 1797-1835. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Taylor-Weiner, A., Pokkalla, H., Han, L., Jia, C., Huss, R., Chung, C., et al. (2021) A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in Nash. Hepatology, 74, 133-147. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Petersen, K.F., Oral, E.A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., et al. (2002) Leptin Reverses Insulin Resistance and Hepatic Steatosis in Patients with Severe Lipodystrophy. Journal of Clinical Investigation, 109, 1345-1350. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Loomba, R., Schork, N., Chen, C., Bettencourt, R., Bhatt, A., Ang, B., et al. (2015) Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. Gastroenterology, 149, 1784-1793. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Park, J., Zhao, Y., Zhang, F., Zhang, S., Kwong, A.C., Zhang, Y., et al. (2023) IL-6/STAT3 Axis Dictates the Pnpla3-Mediated Susceptibility to Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 78, 45-56. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Lotta, L.A., Gulati, P., Day, F.R., Payne, F., Ongen, H., van de Bunt, M., et al. (2016) Integrative Genomic Analysis Implicates Limited Peripheral Adipose Storage Capacity in the Pathogenesis of Human Insulin Resistance. Nature Genetics, 49, 17-26. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Loomba, R., Friedman, S.L. and Shulman, G.I. (2021) Mechanisms and Disease Consequences of Nonalcoholic Fatty Liver Disease. Cell, 184, 2537-2564. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Glass, L.M., Hunt, C.M., Fuchs, M., et al. (2019) Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both? Federal Practitioner: For the Healthcare Professionals of the VA, DoD, and PHS, 36, 64-71.
|
|
[29]
|
Cao, L., An, Y., Liu, H., Jiang, J., Liu, W., Zhou, Y., et al. (2024) Global Epidemiology of Type 2 Diabetes in Patients with NAFLD or MAFLD: A Systematic Review and Meta-Analysis. BMC Medicine, 22, Article No. 101. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Ballestri, S., Nascimbeni, F., Romagnoli, D. and Lonardo, A. (2016) The Independent Predictors of Non-Alcoholic Steatohepatitis and Its Individual Histological Features: Insulin Resistance, Serum Uric Acid, Metabolic Syndrome, Alanine Aminotransferase and Serum Total Cholesterol Are a Clue to Pathogenesis and Candidate Targets for Treatment. Hepatology Research, 46, 1074-1087. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Ballestri, S., Zona, S., Targher, G., Romagnoli, D., Baldelli, E., Nascimbeni, F., et al. (2016) Nonalcoholic Fatty Liver Disease Is Associated with an Almost Twofold Increased Risk of Incident Type 2 Diabetes and Metabolic Syndrome. Evidence from a Systematic Review and Meta-analysis. Journal of Gastroenterology and Hepatology, 31, 936-944. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Duell, P.B., Welty, F.K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., et al. (2022) Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 42, e168-e185. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Sun, D., Targher, G., Byrne, C.D., Wheeler, D.C., Wong, V.W., Fan, J., et al. (2023) An International Delphi Consensus Statement on Metabolic Dysfunction-Associated Fatty Liver Disease and Risk of Chronic Kidney Disease. Hepatobiliary Surgery and Nutrition, 12, 386-403. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Fahy, E., Cotter, D., Sud, M. and Subramaniam, S. (2011) Lipid Classification, Structures and Tools. Biochimica et Biophysica Acta (BBA)—Molecular and Cell Biology of Lipids, 1811, 637-647. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Zhu, Y., Wan, F., Liu, J., Jia, Z. and Song, T. (2024) The Critical Role of Lipid Metabolism in Health and Diseases. Nutrients, 16, Article No. 4414. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Bays, H.E., Bindlish, S. and Clayton, T.L. (2023) Obesity, Diabetes Mellitus, and Cardiometabolic Risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. Obesity Pillars, 5, Article ID: 100056. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年) [J]. 中华心血管病杂志, 2023(3): 221-255.
|
|
[38]
|
Krause, B.R. and Hartman, A.D. (1984) Adipose Tissue and Cholesterol Metabolism. Journal of Lipid Research, 25, 97-110. [Google Scholar] [CrossRef]
|
|
[39]
|
Rong, J., Zhang, Z., Peng, X., Li, P., Zhao, T. and Zhong, Y. (2024) Mechanisms of Hepatic and Renal Injury in Lipid Metabolism Disorders in Metabolic Syndrome. International Journal of Biological Sciences, 20, 4783-4798. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Katsiki, N., Mikhailidis, D.P. and Mantzoros, C.S. (2016) Non-Alcoholic Fatty Liver Disease and Dyslipidemia: An Update. Metabolism, 65, 1109-1123. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Sahini, N. and Borlak, J. (2014) Recent Insights into the Molecular Pathophysiology of Lipid Droplet Formation in Hepatocytes. Progress in Lipid Research, 54, 86-112. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Gluchowski, N.L., Becuwe, M., Walther, T.C. and Farese, R.V. (2017) Lipid Droplets and Liver Disease: From Basic Biology to Clinical Implications. Nature Reviews Gastroenterology & Hepatology, 14, 343-355. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Vvedenskaya, O., Rose, T.D., Knittelfelder, O., Palladini, A., Wodke, J.A.H., Schuhmann, K., et al. (2021) Nonalcoholic Fatty Liver Disease Stratification by Liver Lipidomics. Journal of Lipid Research, 62, Article ID: 100104. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Listenberger, L.L., Han, X., Lewis, S.E., Cases, S., Farese, R.V., Ory, D.S., et al. (2003) Triglyceride Accumulation Protects against Fatty Acid-Induced Lipotoxicity. Proceedings of the National Academy of Sciences, 100, 3077-3082. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X.X., Pandey, S.K., et al. (2007) Inhibiting Triglyceride Synthesis Improves Hepatic Steatosis but Exacerbates Liver Damage and Fibrosis in Obese Mice with Nonalcoholic Steatohepatitis. Hepatology, 45, 1366-1374. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Horn, C.L., Morales., A.L., Savard, C., Farrell, G.C. and Ioannou, G.N. (2021) Role of Cholesterol-Associated Steatohepatitis in the Development of Nash. Hepatology Communications, 6, 12-35. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Cusi, K. (2012) Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. Gastroenterology, 142, 711-725.e6. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Koliaki, C. and Roden, M. (2013) Hepatic Energy Metabolism in Human Diabetes Mellitus, Obesity and Non-Alcoholic Fatty Liver Disease. Molecular and Cellular Endocrinology, 379, 35-42. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Silbernagel, G., Kovarova, M., Cegan, A., Machann, J., Schick, F., Lehmann, R., et al. (2012) High Hepatic SCD1 Activity Is Associated with Low Liver Fat Content in Healthy Subjects under a Lipogenic Diet. The Journal of Clinical Endocrinology & Metabolism, 97, E2288-E2292. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Heyens, L.J.M., Busschots, D., Koek, G.H., Robaeys, G. and Francque, S. (2021) Liver Fibrosis in Non-Alcoholic Fatty Liver Disease: From Liver Biopsy to Non-Invasive Biomarkers in Diagnosis and Treatment. Frontiers in Medicine, 8, Article ID: 615978. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Arguello, G., Balboa, E., Arrese, M. and Zanlungo, S. (2015) Recent Insights on the Role of Cholesterol in Non-Alcoholic Fatty Liver Disease. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1852, 1765-1778. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Vos, D.Y. and van de Sluis, B. (2021) Function of the Endolysosomal Network in Cholesterol Homeostasis and Metabolic-Associated Fatty Liver Disease (MAFLD). Molecular Metabolism, 50, Article ID: 101146. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Liu, L., Wang, C., Hu, Z., Deng, S., Yang, S., Zhu, X., et al. (2024) Not Only Baseline but Cumulative Exposure of Remnant Cholesterol Predicts the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. Environmental Health and Preventive Medicine, 29, Article No. 5. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Lin, R., Sun, Q., Xin, X., Ng, C.H., Valenti, L., Hu, Y., et al. (2024) Comparative Efficacy of THR-β Agonists, FGF-21 Analogues, GLP-1R Agonists, Glp-1-Based Polyagonists, and Pan-Ppar Agonists for MASLD: A Systematic Review and Network Meta-Analysis. Metabolism, 161, Article ID: 156043. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Wang, W., Kong, Y., Wang, X., Wang, Z., Tang, C., Li, J., et al. (2023) Identification of Novel SCD1 Inhibitor Alleviates Nonalcoholic Fatty Liver Disease: Critical Role of Liver-Adipose Axis. Cell Communication and Signaling, 21, Article No. 268. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Vidal-Cevallos, P. and Chávez-Tapia, N. (2024) Resmetirom, the Long-Awaited First Treatment for Metabolic Dysfunction-Associated Steatohepatitis and Liver Fibrosis? Med, 5, 375-376. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Kolodziejczyk, A.A., Zheng, D., Shibolet, O. and Elinav, E. (2018) The Role of the Microbiome in NAFLD and NASH. EMBO Molecular Medicine, 11, EMMM201809302. [Google Scholar] [CrossRef] [PubMed]
|